MK-0518 and GS-9137: two promising integrase inhibitors in the pipeline.

BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2006-01-01

Reilly O'Neal

引用次数: 0

Abstract

Possibly the most exciting news to come out of the 13th Conference on Retroviruses and Opportunistic Infections, held in Denver last February, concerned clinical trials of two experimental drugs in a new class: integrase inhibitors. If successful in further trials, integrase inhibitors could revitalize the treatment regimens of people living with multidrug-resistant HIV.

本刊更多论文

MK-0518和GS-9137:两种有前景的整合酶抑制剂

去年2月在丹佛举行的第13届逆转录病毒和机会性感染会议上，最令人兴奋的消息可能是关于两种新型实验药物的临床试验:整合酶抑制剂。如果在进一步的试验中取得成功，整合酶抑制剂可能会使耐多药艾滋病毒感染者的治疗方案重新焕发活力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation

自引率

0.00%

发文量